Cargando…

Switching to nevirapine-based regimens after undetectable viral load is not associated with increased risk of discontinuation due to toxicity

INTRODUCTION: Due to its good tolerability, favourable cardiovascular risk-profile, low-pill burden and cost, nevirapine-based regimens are an attractive simplification strategy for patients with suppressed viral load (VL). However, current guidelines recommend caution if nevirapine (NVP) is prescri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patterson, Patricia, Socías, Eugenia, Pryluka, Daniel, Lapadula, Pablo, Pérez, Héctor, Cahn, Pedro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P262
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225304/ https://www.ncbi.nlm.nih.gov/pubmed/25397538 http://dx.doi.org/10.7448/IAS.17.4.19794

Ejemplares similares

La détresse psychologique et le stress post-traumatique chez les patients post-COVID-19 réanimés intubés
por: Al Chikhanie, Y., et al.
Publicado: (2022)

Sex differences in apolipoprotein A1 and nevirapine-induced toxicity
por: Marinho, Aline, et al.
Publicado: (2014)

The efficacy, pharmacokinetics, safety and cardiovascular risks of switching nevirapine to rilpivirine in HIV-1 patients: the RPV switch study
por: Rokx, Casper, et al.
Publicado: (2014)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Liver Fibrosis progression using Fibroscan in HIV/HCV coinfected patients with undetectable HIV viral load
por: Perez-Martinez, Laura, et al.
Publicado: (2014)

The impact of nevirapine- versus protease inhibitor-based regimens on virological markers of HIV-1 persistence during seemingly suppressive ART
por: Kiselinova, Maja, et al.
Publicado: (2014)

Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice
por: Costarelli, Silvia, et al.
Publicado: (2014)

Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study
por: Carrero-Gras, Ana, et al.
Publicado: (2014)

Long-term effect of a four-drugs induction regimen for patients with high baseline viral load
por: Maggiolo, Franco, et al.
Publicado: (2014)

Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA
por: Bianco, Claudia, et al.
Publicado: (2014)

Cardiovascular markers of inflammation and serum lipid levels in HIV-infected patients with undetectable viraemia
por: Viskovic, Klaudija, et al.
Publicado: (2014)

Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patients
por: Podzamczer, Daniel, et al.
Publicado: (2014)

Four-drugs regimen containing raltegravir is highly effective in HIV patients starting therapy with >500,000 copies/mL viral load
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Longitudinal comparison of HIV-1 plasma viral load and cellular proviral load
por: Schweitzer, Finja, et al.
Publicado: (2014)

Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters
por: Socías, M Eugenia, et al.
Publicado: (2011)

Who gets single tablet regimens (STR), and why?
por: Tarrier, Laura, et al.
Publicado: (2014)

Service impact of a change in HIV-1 viral load quantification assay
por: Tipple, Craig, et al.
Publicado: (2014)

CSF LPV concentrations and viral load in viral suppressed patients on LPV/r monotherapy given once daily
por: Tiraboschi, Juan, et al.
Publicado: (2014)

Depression in HIV-positive women is associated with changes in antiretroviral treatment regimens
por: Philippe Küpper-Tetzel, Claus, et al.
Publicado: (2014)

Facilitators and barriers to cotrimoxazole and nevirapine prophylaxis among HIV exposed babies: a qualitative study from Harare, Zimbabwe
por: Sibanda, E, et al.
Publicado: (2012)

Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL study
por: Cahn, Pedro, et al.
Publicado: (2014)

Patients’ willingness to take separate component antiretroviral therapy regimens for HIV in the Netherlands
por: Engelhard, Esther, et al.
Publicado: (2014)

Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort
por: Di Biagio, Antonio, et al.
Publicado: (2014)

Virological outcomes in ARV-naïve patients switching or not from a first successful boosted PI-regimen to efavirenz, nevirapine or abacavir regimens
por: Bommenel, T, et al.
Publicado: (2010)

Treatment outcome in HIV+ patients receiving 3- or 4-drug regimens during PHI
por: Maria Bottani, Giulia, et al.
Publicado: (2014)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

Time to virologic failure for patients taking their first antiretroviral regimen and the subsequent resistance profiles
por: Crouzat, Frederic, et al.
Publicado: (2014)

Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting
por: Gianotti, Nicola, et al.
Publicado: (2014)

Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment
por: Sweet, Donna, et al.
Publicado: (2014)

Nephrolithiasis and renal failure among patients exposed to atazanavir, other PIs and PI-free regimens
por: Nkhoma, Ella, et al.
Publicado: (2014)

The prevalence and predictive value of dipstick urine protein in HIV-positive persons in Europe
por: Mocroft, Amanda, et al.
Publicado: (2014)

Single-tablet regimen is associated with reduced efavirenz withdrawal in antiretroviral naïve or switching for simplification HIV-infected patients
por: Fabbiani, M, et al.
Publicado: (2012)

DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI
por: Di Yacovo, Silvana, et al.
Publicado: (2014)

Efficacy and safety of rilpivirine-based regimens in treatment-experienced HIV-1 infected patients: a prospective cohort study
por: Gazaignes, Sandrine, et al.
Publicado: (2014)

Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens
por: Giacomelli, Andrea, et al.
Publicado: (2014)

Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala
por: Laker, Eva, et al.
Publicado: (2014)

Efficacy and safety of etravirine-containing regimens in a large cohort of HIV/HCV coinfected patients according to liver fibrosis
por: Luis Casado, Jose, et al.
Publicado: (2014)

Safety analysis of raltegravir/truvada regimen in HIV/HCV co-infected patients without switchback after HCV treatment
por: Ehret, Robert, et al.
Publicado: (2014)

Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort
por: Saracino, Annalisa, et al.
Publicado: (2014)

Low level HIV viremia is more frequent under protease-inhibitor containing firstline therapy than under NNRTI-regimens
por: Wiesmann, Frank, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vpm01q2d9d0fl15faoirmfchl9